NCT04393805

Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 744 (actual)
• Sponsor: Quovadis Associazione · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

Detailed description

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19. Furthermore, the possible association between the observed clinical evolution and the type of antithrombotic prophylaxis performed (class of drug and dose intensity) will be assessed in a large cohort of patients hospitalized in the various participating hospitals in the Veneto region and observed with follow-up. in the short term, gathering information on: Clinical outcomes, Survival, Concomitant pathologies, Adverse events of anticoagulant drugs, Interactions with other concomitant drugs, and Risk factors. The collected data, suitably anonymized, will be used to produce scientific works, the standardization of care paths, and the planning of targeted training events.

Conditions

• COVID-19
• Hypercoagulability

Interventions

Type	Name	Description
DRUG	Low Molecular Weight Heparin	Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin

Timeline

• Start date: 2020-06-01
• Primary completion: 2021-02-26
• Completion: 2021-02-26
• First posted: 2020-05-19
• Last updated: 2021-03-18

Locations

1 site across 1 country: Italy

Regulatory

• FDA-regulated drug study